Semaglutide and Virtual Coaching for Weight Loss Before Kidney Transplant
Tests semaglutide and virtual weight coaching in adults with obesity and kidney disease.
Plain-language title generated from the registry record
Registry title: Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
Key facts
- Where
- London, CanadaSee the site
- Phase
- Phase 4
Where in Canada
- London Health Sciences CentreLondon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Western University, Canada
- Trial code
- NCT06396416
- Record updated
- 29 June 2026
- Original description
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.Read full original descriptionShow less
Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)
OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial.
We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant. Subjects will either be enrolled on a virtual weight management program or continue their usual care.
Inclusion: Adults aged 18 years or older; BMI; 35 kg/m\^2; 10% risk of ESKD requiring renal replacement therapy over 2 years or receiving dialysis.
Exclusion: No access to semaglutide via drug coverage; Known contraindication to a GLP-1RA (pancreatitis, personal or family history of medullary thyroid cancer, hypersensitivity); Type 1 diabetes; Pregnant, breastfeeding or planning to become pregnant; Currently in a GLP-1RA or GLP-1RA/GIP study or planning to be in one.